A detailed history of Oppenheimer Asset Management Inc. transactions in Landec Corp \Ca\ stock. As of the latest transaction made, Oppenheimer Asset Management Inc. holds 43,001 shares of LNDC stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,001
Previous 23,907 79.87%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

BUY
N/A
19,094 Added 79.87%
43,001 $0
Q4 2023

Feb 13, 2024

SELL
N/A
-9,625 Reduced 28.7%
23,907 $0
Q3 2023

Nov 07, 2023

SELL
N/A
-31,443 Reduced 48.39%
33,532 $0
Q2 2023

Aug 02, 2023

BUY
N/A
6,975 Added 12.03%
64,975 $0
Q1 2023

May 10, 2023

SELL
N/A
-19,221 Reduced 24.89%
58,000 $0
Q4 2022

Feb 06, 2023

SELL
$0.0 - $9.95 $0 - $46,665
-4,690 Reduced 5.73%
77,221 $0
Q3 2022

Nov 14, 2022

SELL
$8.57 - $11.57 $6,033 - $8,145
-704 Reduced 0.85%
81,911 $728,000
Q2 2022

Aug 08, 2022

BUY
$8.84 - $11.64 $190,042 - $250,236
21,498 Added 35.18%
82,615 $824,000
Q1 2022

May 12, 2022

BUY
$10.07 - $11.93 $66,844 - $79,191
6,638 Added 12.18%
61,117 $708,000
Q4 2021

Feb 02, 2022

BUY
$7.95 - $11.24 $5,366 - $7,587
675 Added 1.25%
54,479 $605,000
Q3 2021

Nov 12, 2021

BUY
$9.22 - $12.44 $31,560 - $42,582
3,423 Added 6.79%
53,804 $496,000
Q2 2021

Aug 03, 2021

BUY
$9.91 - $12.78 $35,656 - $45,982
3,598 Added 7.69%
50,381 $567,000
Q1 2021

May 17, 2021

BUY
$10.44 - $12.22 $231,841 - $271,369
22,207 Added 90.36%
46,783 $496,000
Q4 2020

Feb 11, 2021

BUY
$9.3 - $11.77 $114,436 - $144,829
12,305 Added 100.28%
24,576 $267,000
Q3 2020

Nov 13, 2020

BUY
$7.59 - $10.8 $93,136 - $132,526
12,271 New
12,271 $119,000

Others Institutions Holding LNDC

About LANDEC CORP \CA\


  • Ticker LNDC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 29,595,600
  • Description
  • Landec Corporation operates as a diversified health and wellness company. The company manufactures pharmaceutical-grade sodium hyaluronate (HA)-based biomaterials for primary use in the ophthalmic and orthopedic markets. It also provides product development services to its partners for HA-based, as well as non-HA based, aseptically formulated, a...
More about LNDC
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.